RP72 / Rise Biopharma - LARVOL DELTA

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Rise Biopharmaceuticals, Inc. | Trial completion date: Dec 2022 ➔ Dec 2025 | Trial primary completion date: Oct 2022 ➔ Oct 2024

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Rise Biopharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Rise Biopharmaceuticals, Inc.; Initiation date: Nov 2020 ➔ Mar 2021

Clinical • Combination therapy • Monotherapy • Trial initiation date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Rise Biopharmaceuticals, Inc.; Trial completion date: Jun 2022 ➔ Dec 2022; Initiation date: Apr 2020 ➔ Nov 2020; Trial primary completion date: Apr 2022 ➔ Oct 2022

Clinical • Combination therapy • Monotherapy • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Rise Biopharmaceuticals, Inc.

Clinical • Combination therapy • Monotherapy • New P1 trial • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor